A validated size exclusion chromatography method coupled with fluorescence detection for rapid quantification of bevacizumab in ophthalmic formulations

• Published in: Journal of Pharmaceutical and Biomedical Analysis
• Main Author: Jirjees F.; Soliman K.; Wang Y.; Sonawane R.; Sheshala R.; Jones D.; Thakur R.R.S.
• Format: Article
• Language: English
• Published: Elsevier B.V. 2019
• Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066322059&doi=10.1016%2fj.jpba.2019.05.038&partnerID=40&md5=d6c196af7aefc5472cc4c5c39e2eff5e

Bevacizumab is a full-length human monoclonal antibody used to treat various neovascular diseases such as wet age-related macular degeneration (AMD), diabetic eye disease and other problems of the retina. Monthly intravitreal injections of bevacizumab (Avastin®) are effective in the treatment of wet AMD. However, there is a growing demand in the development of sustained release ophthalmic formulations. Therefore, this study aims, for the first time, to develop a rapid, simple, and sensitive method using size exclusion chromatography coupled with fluorescence detection for routine quantification of bevacizumab in ophthalmic formulations and during in vitro release studies. The selected chromatographic conditions included an aqueous mobile phase composed of 35 mM sodium phosphate buffer and 300 mM sodium chloride (pH 6.8), a flow rate of 0.5 mL/min, and the fluorescence detector was operated at excitation and emission wavelengths of 280 and 340 nm, respectively. The peak area-concentration relationship maintained its linearity over concentration range of 0.1–20 μg/mL (R2 = 0.9993), and the quantitation limit was 100 ng/mL. The method was validated for specificity, accuracy, precision, and robustness. The developed method had a run time of 6 min at temperature 25 °C, making it a unique validated method for rapid and cost-effective quantification of bevacizumab. © 2019 Elsevier B.V.